Ruthenium-based core-shell nanoparticles with exceptional in vitro biocompatibility
Loading...
Date
2017-12-31
Authors
Michálková, Hana
Strmiska, Vladislav
Dostálová, Simona
Michálek, Petr
Křížková, Soňa
Kopel, Pavel
Hynek, David
Richtera, Lukáš
Adam, Vojtěch
Heger, Zbyněk
0000-0002-7036-1640Advisor
Referee
Mark
Journal Title
Journal ISSN
Volume Title
Publisher
Mendel University in Brno
Abstract
The current study demonstrates design preparation and characterization of biocompatible hybrid ruthenium core-shell nanoparticles (RuNPs) coated with polyvinylpyrrolidone (PVP) and polyoxyethylene stearate (POES). The resulting RuNPs were loaded with doxorubicin, as model anticancer drug. Resulting complex has an exceptional stability in physiological conditions. The cytotoxic effects of the complex were tested using cell lines representing breast and ovarian cancers and neuroblastoma. Although bare RuNPs had only negligible cytotoxicity, RuPDox caused an enhancement of doxorubicin cytotoxicity when compared to free doxorubicin. RuPDox promoted significantly increased stability of doxorubicin in human plasma and pronounced hemocompatibility assayed on human red blood cells. Results demonstrate that biocompatible RuNPs could have a great potential as versatile nanoplatform to enhance efficiency of anticancer therapy.
Description
Citation
Document type
Peer-reviewed
Document version
Published version
Date of access to the full text
Language of document
en
Study field
Comittee
Date of acceptance
Defence
Result of defence
Document licence
(C) Mendel University in Brno